Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the systemic levels of beclomethasone 17
monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP
HFA with the systemic levels of 17 BMP after administration of orally inhaled BDP HFA in
healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries